Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,883 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrates Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

NCT03962998
View directory record Official record
Conditions
Crohn Disease
Interventions
Lactulose/Rhamnose solution, MB-102
Drug
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

NCT01922921
View directory record Official record
Conditions
HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
HER-2/neu Intracellular Domain Protein, Laboratory Biomarker Analysis, Pertuzumab, Placebo, Polysaccharide-K, Trastuzumab
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

NCT00004914
View directory record Official record
Conditions
Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, physical therapy
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 20, 2026, 7:35 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, CC-99282
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
18
States / cities
Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

NCT01008462
View directory record Official record
Conditions
B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Small Lymphocytic Lymphoma, t(14;16), t(4;14), T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

NCT02068846
View directory record Official record
Conditions
HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion
Interventions
Ciprofloxacin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 20, 2026, 7:35 AM EDT
Terminated Not applicable Interventional Results available

N-Acetylcysteine for Patients With COPD and Chronic Bronchitis

NCT01739790
View directory record Official record
Conditions
COPD, Chronic Bronchitis
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

Alkontrol-herbal Effects on Alcohol Drinking

NCT03099590
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Use Disorder, Alcohol Abstinence
Interventions
kudzu extract, puerarin, Placebo control
Dietary Supplement
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 20, 2026, 7:35 AM EDT
Terminated Not applicable Interventional Results available

Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia

NCT00547703
View directory record Official record
Conditions
Non Ulcer Dyspepsia
Interventions
Nortriptyline, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns

NCT00000642
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Brooklyn, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Not applicable Interventional

The Effects of Fiber Fortified Foods to the Diets of Chronic Kidney Disease Patients

NCT01842087
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Control Food, Fiber Fortified Food
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Not applicable Interventional

A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

NCT00587093
View directory record Official record
Conditions
Ovarian Cancer
Interventions
CA 125 and CT scan
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
5
States / cities
Baltimore, Maryland • Basking Ridge, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Not applicable Interventional

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

NCT06018480
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Creatine Monohydrate, Maltodextrin (Placebo)
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Trials Which Assessed Consumption of Slowly Digestible Carbohydrates for 21 Days on Gastric Emptying Rates

NCT05430061
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
slowly digestible carbohydrate
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

NCT00002676
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
21
States / cities
Scottsdale, Arizona • Denver, Colorado • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 3 Interventional

Ulimorelin Study of Efficacy and Safety (ULISES 007)

NCT01285570
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Ulimorelin Intravenously (IV), 5% dextrose in water
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 20, 2026, 7:35 AM EDT
Recruiting Phase 4 Interventional

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

NCT06714864
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
(taurolidine and heparin) catheter lock solution, Standard of Care
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Not applicable Interventional

The Impact of Food Order on Glycemic Excursions in Type 2 Diabetes Assessed by Continuous Glucose Monitoring

NCT04738799
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Carbohydrate-Last Meal Sequence, Carbohydrate-First Meal Sequence
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00873093
View directory record Official record
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, bortezomib, pegaspargase, methotrexate, etoposide phosphate, cyclophosphamide, filgrastim, leucovorin calcium, laboratory biomarker analysis, High Dose MTX
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
157
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 20, 2026, 7:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Genetics of Asthma - Bronchoscopy Studies

NCT00644514
View directory record Official record
Conditions
Atopic Asthma, Healthy
Interventions
Endotoxin - lipopolysaccharide (LPS)
Biological
Lead sponsor
John Sundy
Other
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

NCT02465632
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 20, 2026, 7:35 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation

NCT00646763
View directory record Official record
Conditions
Cytokines
Interventions
G-CSF, GM-CSF administered at extremities, G-CSF and GMCSF administered at abdomen
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Midazolam, Fexofenadine, Digoxin
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 7:35 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

NCT00004255
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Chimeric Therapies
Industry
Eligibility
12 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
15
States / cities
La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 20, 2026, 7:35 AM EDT